Restoring confidence post-Invossa incident was my priority
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.01.09 16:34:38
°¡³ª´Ù¶ó
0
Kim Sun Jin, CEO of Kolon Life Science
Newly appointed in March 2023, Kim successfully resumed Invossa U.S. trials and focused on instilling confidence within the company
In his 2nd year, restructuring toward ¡®reinforcing R&D¡¯¡¦ ¡°Strengthening mid-to-long-term growth in new drug development¡±
¡°Even in the face of failure, do not worry. As the CEO of the company, I will take full responsibility for everything. We will engage in frequent communication. Once we reach a consensus after thorough discussions, I will bear responsibility for the outcome, regardless of the outcome.¡±
In his inaugural speech in March of the previous year, the newly appointed CEO, Kim Sun Jin, of Kolon Life Science sent the message to the executive and staff members. Kim dedicated a year of relentless efforts toward enhancing the corporate mood after assuming the leadership position at Kolon Life Science.
¡ãKim Sun Jin, CEO of Kolon Life Science
CEO Kim became affiliated with Kolon Life Sciences after joining Kolon TissueGene as an ind
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)